Global biopharmaceutical company Almirall is set to take part in the Framework for ClInicaL trIal participants’ daTA reutilisation for a fully Transparent and Ethical ecosystem (FACILITATE) project to enable the use of clinical trial data by participants.

The patient-driven Innovative Medicines Initiative (IMI) project is aimed at creating a framework for participant data access and reuse for a fully compliant ecosystem.

The primary objective of FACILITATE is to help return the data related to the clinical trial to the participants, ready for reuse in either research going forward or in healthcare practices.

Almirall FACILITATE project leader Diego Herrera said: “The launch of FACILITATE further advances patient empowerment in clinical trials.

“At Almirall, we are excited to contribute to this patient-driven IMI project, with our solid experience in clinical trials and our commitment to ethics and transparency. This project is fully aligned with our patient-centricity strategy aimed at improving their quality of life.”

The project is based on a technology platform, which is patient-centred and data-driven, and comprises 27 partners from 17 EU and non-EU Member States.

Hospitals, universities, patient associations, small and medium-sized enterprises, and the European Federation of Pharmaceutical Industries and Associations (EFPIA) members are the participants included in the project.

The Università degli Studi di Modena e Reggio Emilia is the project coordinator.

Last year, the project was approved by the IMI Joint Undertaking (European Commission and EFPIA) and has been launched this year, along with the FACILITATE website.

It has secured funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) that is supported by the European Union’s Horizon 2020 research and innovation programme and EFPIA.